ST Pharm Secures First Japanese Patent for mRNA-LNP Platform Technology STP1244
核心洞察
ST Pharm (搜索) has secured its first Japanese patent for ionizable lipid STP1244 (搜索), a core component of its proprietary mRNA-LNP platform STLNP (搜索), marking a significant milestone in its intellectual property portfolio.
The patent covers both the key raw material STP1244 (搜索) and the complete LNP formulation STL1244 (搜索), establishing comprehensive technology rights from components to finished formulations.
The company is pursuing patent protection in nine countries including Korea, the United States, Europe, and China, positioning itself as a major player in the rapidly growing global mRNA therapeutics market.
ST Pharm (搜索) announced on April 13 that it has completed registration of a Japanese patent for the ionizable lipid 'STP1244 (搜索)', a key raw material in its proprietary mRNA-LNP platform 'STLNP (搜索)', as well as for the LNP formulation (STL1244 (搜索)) that uses this material. This represents the first registered patent among those related to the STLNP platform, marking a significant milestone for the company's intellectual property strategy.
Core Technology Platform Secured
Ionizable lipids are substances that enhance the intracellular delivery efficiency of mRNA and promote endosomal escape, making them a core component that determines the performance of lipid nanoparticles (LNPs). LNP serves as an essential delivery vehicle that transports mRNA into cells, and STP1244 (搜索) is a key material that enhances delivery efficiency and facilitates endosomal escape in this process.
With this registration, ST Pharm (搜索) has secured a technology portfolio covering everything from key raw materials to the finished formulation. The company has now acquired comprehensive rights to its LNP technology based on its self-developed ionizable lipid 'STP1244 (搜索),' extending beyond formulation technology alone.
Global Patent Strategy Underway
Currently, additional patent reviews are underway in nine countries, including Korea, the United States, Europe, and China. ST Pharm (搜索) is pursuing patent examination procedures starting with Japan and plans to further expand its global rights acquisition going forward.
"With this Japanese patent registration, we have established a technology portfolio spanning from core LNP components to complete formulations," an ST Pharm (搜索) official explained. "This demonstrates our technical capabilities and business expansion potential as an mRNA-LNP contract development and manufacturing organization (CDMO) in response to the rapidly growing global mRNA therapeutics and vaccine market."
Strategic Platform Development
A representative from ST Pharm (搜索) stated, "Following the Japanese patent registration for 'SmartCap (搜索)' last March, the registration for STLNP (搜索) means we now possess both core platform technologies for mRNA drug development." The company now holds intellectual property rights for two critical mRNA platform technologies.
Future Applications and Market Expansion
ST Pharm (搜索) plans to expand its role in the development of mRNA cancer (搜索) vaccines and mRNA-based in-vivo CAR-T therapies. "Based on technology certified in advanced markets, we will play a pivotal role not only in mRNA cancer vaccines but also in the development of mRNA-based in-vivo chimeric antigen receptor T-cell (CAR-T) therapeutics, which have been gaining attention recently," an ST Pharm official emphasized.
The patent registration positions ST Pharm (搜索) as a significant player in the rapidly growing global mRNA therapeutics and vaccine market, with comprehensive technology rights that span from raw materials to finished formulations in the critical LNP delivery system space.